We are live on ! Find out more

Acumen Pharmaceuticals

ABOS

Market cap $15.2M

0.2101 USD

-2.0799

90.83%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

0.2226

+0.0125

5.95%

1 day

-90.83%

5 days

-90.14%

1 month

-90.54%

3 months

-90.32%

6 months

-91.21%

Year to date

-89.6%

1 year

-90.54%

5 years

-98.49%

10 years

-98.95%

About: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Employees: 61

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 6.3%

Neutral 93.8%

Negative 0%

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint

-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS) at 18 months compared to placebo at either dose; key secondary endpoints, including CDR-SB, also did not achieve statistical significance -- -- Acumen to cease clinical development of sabirnetug, preserve cash and explore strategic options --

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint

Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's Readout

Acumen Pharmaceuticals is rated a speculative Buy ahead of November 2026 Phase 2 ALTITUDE-AD data for sabirnetug in early Alzheimer's disease. I estimate ABOS fair value at $2.57 per share, a 14% premium to market, based on risk-adjusted NPV and anticipated financing needs. Key upside hinges on sabirnetug achieving ≥30% iADRS slowing with manageable ARIA risk; subpar efficacy or safety would negate the thesis.

Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's Readout

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript

Acumen Pharmaceuticals Q3 Earnings Call Highlights

Acumen Pharmaceuticals NASDAQ: ABOS said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed to target soluble amyloid-beta oligomers in patients with Alzheimer's disease.

Acumen Pharmaceuticals Q3 Earnings Call Highlights

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in November 2026 IND filing for the Enhanced Brain Delivery™ (EBD®) program lead clinical candidate targeted for mid-2027 Cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass.

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

NEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present three key poster presentations at the upcoming 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in Boston. The presentations focus on Acumen's Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) for the treatment of early AD, including preliminary baseline characteristics of study participants, study participant and partner experience, and treatment expectations and motivations. The conference will be held November 16-19, 2026, both in-person and online. “These presentations reflect Acumen's commitment to understanding the biology of early AD as well as the full experience, including the perspectives of patients and care partners living with it every day,” said Eric Siemers, M.D., Chief Medical Officer of Acumen Pharmaceuticals. “These important insights from our study collaborators and participants in ALTITUDE-AD help keep their needs at the center of our efforts to advance sabirnetug as a potential treatment of choice for AD.”

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter financial results on Monday, Oct. 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

Zacks Investment Research

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET.

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

See News Rankings

Price charts implemented using Lightweight Charts™